A5067043341- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Cancer Treatment and Pharmacology
- Cardiac tumors and thrombi
- Veterinary Oncology Research
- melanin and skin pigmentation
- Adrenal and Paraganglionic Tumors
- Chemotherapy-related skin toxicity
- Hemoglobinopathies and Related Disorders
- Cancer and Skin Lesions
- Hematopoietic Stem Cell Transplantation
- Chemokine receptors and signaling
- Hematological disorders and diagnostics
- Organ Transplantation Techniques and Outcomes
- Multiple and Secondary Primary Cancers
NYU Langone Health
2018-2020
Icahn School of Medicine at Mount Sinai
2015-2016
Mount Sinai Hospital
2015
UConn Health
2012
Dana-Farber Cancer Institute
2009
Harvard University
2009
Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further will be. Moreover, there are no data on optimal sequencing of these treatments standard other novel agents. In a multicenter, retrospective analysis, we investigated whether exposure CBT could sensitize HL subsequent therapy.Seventeen...
Summary Patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL) have limited options for salvage, and checkpoint blockade therapy (CBT) has little efficacy. Usage in solid malignancies suggests that CBT sensitises tumours to subsequent chemotherapy. We performed the first analysis of on NHL treatment. Seventeen North American centres retrospectively queried records. The primary aim was evaluate overall response rate (ORR) post‐CBT Secondary aims included progression‐free survival...
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation treatment beyond progression (TBP); however, longitudinal benefit this approach is unclear. We therefore performed a retrospective analysis 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 stopped ICB at initial (non-TBP cohort). The cohort for median 4.7 months after delayed subsequent by 6.6 months. Despite receiving more prior lines...
e21524 Background: Immunotherapy (IT) has become the mainstay treatment for advanced cutaneous malignancies (ACM), with superior efficacy and tolerability than chemotherapy. Use in elderly patients (pts) is not well investigated. Methods: We conducted an IRB-approved, single institution, retrospective chart review of 53 pts, ages 75-96, ACM treated IT to assess best response (BR) immune related adverse events (IRAE). Results: 38 men 15 women were included, KPS 0-2. At therapy initiation 17...